Clinical trial
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
NCT00495872 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00495872 |
|---|---|
| Title | Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor |
| Official title | A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | Dasatinib, Erlotinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, Valproic Acid |
| Enrollment | 204 |
| Start date | Jun 1, 2007 |
| Primary completion | Oct 1, 2012 |
| First posted | Jul 3, 2007 |
| Last update posted | Oct 18, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: